PLANO, Texas, June 16, 2011 /PRNewswire/ -- MacuCLEAR, Inc., a specialty clinical stage pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today that Philip G. Ralston, president and CEO, will be presenting at OneMedForum New York 2011 on Thursday, June 23, 2011 at 11:30 a.m. EDT at The Roosevelt Hotel in New York City.
OneMedForum will focus on critical success factors for building companies internationally. In addition to presentations by more than 70 emerging medical technology companies, delegates will gain insights in the critical areas of regulatory approval, reimbursement and distribution and sales organizations in the EU and U.S.
Concurrently, Mr. Ralston will also present at the 2011 BIO Business Forum during the annual BIO International Convention at the Walter E. Washington Convention Center in Washington, D.C. Mr. Ralston's presentation will be given on Wednesday, June 29, 2011 at 9:15 a.m. EDT in the Adams Morgan Room. The presentation will include an overview of the company with emphasis on the lead proprietary compound, MC-1101, which is being developed for the treatment of the dry form of age-related macular degeneration (AMD).
The BIO Business Forum is a unique platform for biotechnology and pharmaceutical companies, academic research institutions and investors from around the world to gather and discuss strategic opportunities. This forum is featured within the BIO International Convention, the largest global event for the biotechnology industry, offering networking and partnering opportunities with policymakers, scientists, CEOs and newsmakers and hundreds of sessions covering biotech trends, policy issues and technological innovations.
About MacuCLEAR, Inc.
MacuCLEAR, Inc. is a clinical-stage specialty pharmaceutical company focused on developing innovative treatments for vascular and retinal diseases of the eye. Its lead compound MC-1101 is a novel, topically delivered eye drop drug for treating and stopping the progression of age-related macular degeneration (AMD) from the early-stage (Dry AMD) to the late-stage (Wet AMD) by improving ocular blood flow.
The active ingredient of MC-1101 has been previously approved by the FDA as an oral antihypertensive drug. MC-1101 has been granted 505 (b) 2 status and has formal Fast Track designation by the FDA. In addition to MC-1101, MacuCLEAR's portfolio includes 11 compounds that are being developed for diabetic retinopathy, second-generation treatment for AMD and other vascular diseases of the eye.
George C.Y. Chiou, Ph.D., who led the development of Timolol, a pioneering treatment for glaucoma, invented this technology at Texas A&M University.
Founded in 2006, MacuCLEAR is a privately held Plano, TX-based company. For additional information, please visit www.macuclear.com.
About Age-Related Macular Degeneration
AMD is the leading cause for blindness in the world in people 50 and older. Dry AMD afflicts 90 percent of AMD sufferers and currently has no approved drug treatments.
|SOURCE MacuCLEAR, Inc.|
Copyright©2010 PR Newswire.
All rights reserved